MarketCapExport financials
PRA Health Sciences, Inc. (PRAH)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
TelegramPRA Health Sciences, Inc. Income Statement 2020-2011 | PRAH
Brief overview of revenue and earnings at PRA Health Sciences, Inc.
The figures are compared over a five-year interval. Revenue reported by PRA Health Sciences, Inc. was $1.6 billion at the beginning of the period and $3.2 billion at the end. Overall revenue changed by +97.2%, equal to an annualized rate of about 14.6%. Revenue followed a strong upward trend without signs of stagnation.
The gross result shifted from 489 million dollars to 869 million dollars, or +77.5%. Gross profit as a share of revenue changed from 30.3% to 27.3%. The business retained less gross profit from each unit of revenue.
The operating result measured by EBITDA moved from $243 million to $416 million, or +71.1%. Operating performance weakened relative to revenue. EBITDA margin moved from 15.1% to 13.1%. Operating profitability remained broadly stable.
The five-year change in net income was +141%: from 81.8 million dollars to 197 million dollars. Net profitability strengthened faster than the top line.
The market value of the business moved from $2.6 billion to $7.9 billion, or +204.6%. A large part of future progress may already be reflected in the valuation.
What the figures show
The financial profile remains mixed, with strengths and risks moving in different directions. The positive side is supported by improving net profitability and revenue expansion. The most visible risks are pressure on operating profitability and pressure from direct costs. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement PRA Health Sciences, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
7.87 B | 6.53 B | 6.72 B | 5.73 B | 3.44 B | 2.58 B | 1.12 B | - | - | - |
Shares |
63.8 M | 64.5 M | 64.1 M | 62.4 M | 60.8 M | 60 M | 42.9 M | - | - | - |
Net Income |
197 M | 243 M | 154 M | 86.9 M | 68.2 M | 81.8 M | -35.7 M | - | -2.71 M | - |
Revenue |
3.18 B | 3.07 B | 2.87 B | 2.26 B | 1.81 B | 1.61 B | 1.46 B | - | 700 M | - |
EBITDA |
416 M | 482 M | 429 M | 343 M | 277 M | 243 M | 153 M | - | 77.9 M | - |
Operating Expenses |
585 M | 510 M | 484 M | 400 M | 339 M | 324 M | 351 M | - | 191 M | - |
General and Administrative Expenses |
453 M | 395 M | 372 M | 322 M | 270 M | 246 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company PRA Health Sciences, Inc. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K |  USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 257.93 | 1.18 % | $ 28.6 B | USA |
 |
Danaher Corporation
DHR
|
$ 230.45 | 1.76 % | $ 164 B | USA |
 |
IDEXX Laboratories
IDXX
|
$ 676.3 | 0.83 % | $ 54.4 B | USA |
 |
Illumina
ILMN
|
$ 213.05 | 2.43 % | $ 33 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 100.61 | -0.09 % | $ 6.79 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
$ 653.24 | 2.88 % | $ 18.8 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 722.36 | 2.64 % | $ 35.5 B |  Schweiz |
 |
Natera
NTRA
|
$ 319.38 | -12.2 % | $ 43.7 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 338.13 | 8.07 % | $ 16.8 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 30.33 | -0.57 % | $ 28.8 B |  Niderland |
 |
QIAGEN N.V.
QGEN
|
$ 50.36 | -0.98 % | $ 10.9 B | Niderland |
 |
RadNet
RDNT
|
$ 75.83 | -2.79 % | $ 5.7 B | USA |
 |
Senseonics Holdings
SENS
|
$ 8.58 | 7.38 % | $ 358 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
$ 2.17 | -10.91 % | $ 143 M | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 694.85 | 2.62 % | $ 262 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Trinity Biotech plc
TRIB
|
$ 6.07 | 2.97 % | $ 2.18 B |  Irlanda |
 |
Brainsway Ltd.
BWAY
|
$ 11.12 | 4.81 % | $ 378 M |  Israel |
 |
VolitionRx Limited
VNRX
|
$ 0.2 | 3.39 % | $ 25.2 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 458.04 | 1.06 % | $ 27.3 B | USA |
 |
Exagen
XGN
|
$ 5.79 | -23.82 % | $ 125 M | USA |
 |
Guardant Health
GH
|
$ 151.28 | -1.4 % | $ 19 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 366.98 | 1.02 % | $ 30.5 B | USA |
 |
IQVIA Holdings
IQV
|
$ 271.72 | 2.59 % | $ 46.7 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
Celcuity
CELC
|
$ 66.73 | 3.9 % | $ 3.12 B | USA |
 |
DexCom
DXCM
|
$ 79.42 | -5.97 % | $ 31 B | USA |
 |
Agilent Technologies
A
|
$ 175.14 | 1.97 % | $ 49.7 B | USA |
 |
Castle Biosciences
CSTL
|
$ 32.49 | -4.99 % | $ 942 M | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.16 | 4.29 % | $ 103 K | USA |
|
Biodesix
BDSX
|
$ 8.51 | -57.13 % | $ 64.3 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.15 | 4.54 % | $ 6.26 M | USA |
 |
Bioventus
BVS
|
$ 10.61 | -0.66 % | $ 707 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 23.68 | 26.9 % | $ 729 M | USA |
 |
CareDx, Inc
CDNA
|
$ 78.47 | 2.8 % | $ 4.18 B | USA |